Close Menu

NEW YORK – Meridian Bioscience said on Wednesday that it has submitted its Curian analyzer and Curian HpSA assay for H. pylori infection diagnosis to the US Food and Drug Administration for review.

The platform and assay use fluorescent lateral flow technology to detect Helicobacter pylori antigens in human stool, and the assay is also intended to monitor patients' responses during and after therapy.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.